{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:55:19Z","timestamp":1790164519878,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":1254,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Aventis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1093\/annonc\/mdw098","type":"journal-article","created":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T02:13:19Z","timestamp":1457057599000},"page":"1041-1047","source":"Crossref","is-referenced-by-count":55,"title":["Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial"],"prefix":"10.1016","volume":"27","author":[{"given":"J.R.","family":"Mackey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pie\u0144kowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Crown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sehdev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Semiglazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Press","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Hou\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Drevot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hitier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bensfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Eiermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdw098_bb0010","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials","volume":"379","author":"Peto","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdw098_bb0015","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw098_bb0020","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial","volume":"24","author":"Roche","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw098_bb0025","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw098_bb0030","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2015.60.9271","article-title":"Long-term follow-up of the E1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer","volume":"33","author":"Sparano","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw098_bb0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","article-title":"Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial","volume":"14","author":"Mackey","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdw098_bb0040","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2010.28.5437","article-title":"Phase III study of doxorubicin\/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial","volume":"29","author":"Eiermann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw098_bb0045","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","article-title":"et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer","volume":"362","author":"Swain","year":"2010","journal-title":". N Engl J Med"},{"key":"10.1093\/annonc\/mdw098_bb0050","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1200\/JCO.2012.48.1275","article-title":"et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial","volume":"31","author":"Swain","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdw098_bb0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw098_bb0060","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature10933","article-title":"The clonal and mutational evolution spectrum of primary triple-negative breast cancers","volume":"486","author":"Shah","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdw098_bb0065","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdw098_bb0070","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419356364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419356364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/6\/1041\/16701408\/mdw098.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:57:34Z","timestamp":1624694254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419356364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0923753419356364"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdw098","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}